NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
28 Nov 2018

BioClin Therapeutics Announces Name Change to Rainier Therapeutics

BioClin Therapeutics, Inc., today announced the company is changing its name to Rainier Therapeutics, Inc.
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting<
30 Oct 2018

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting

All Patients Met Preliminary Efficacy Endpoint to Date with Evidence of Biological Activity
26 Oct 2018

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Galecto Biotech AB, today announced the successful closing of a €79 million series C financing co-led by Ysios Capital and OrbiMed.
24 Oct 2018

JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury

JAMA paper to be presented at ESICM conference in Paris.
23 Oct 2018

Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology

Laboratoris Sanifit S.L., today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical Pharmacology.
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure<
18 Oct 2018

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like.
16 Oct 2018

Kala Pharmaceuticals submits new drug application to U.S. Food and Drug Administration for KPI-121 0.25% for dry eye disease

Kala Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%.
03 Oct 2018

Kala Pharmaceuticals announces pricing of public offering of 7,500,000 shares of common stock

Kala Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.25 per share, before offering discounts.
02 Oct 2018

Kala Pharmaceuticals announces financing from Athyrium Capital Management totaling $110 Million

Kala Pharmaceuticals, Inc. today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm.
Minoryx Therapeutics raises €21.3M in Series B funding round<
26 Sep 2018

Minoryx Therapeutics raises €21.3M in Series B funding round

Minoryx Therapeutics, today announces the completion of a Series B funding round of €21.3M.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.